Drugs
-
Gonadotropin-Releasing Hormone (GnRH) Agonists Information
Gonadatripon-Releasing Hormone (GnRH) Agonists are medications used in the treatment of prostate cancer.
To report any serious adverse events associated with the use of these drugs, please contact the FDA MedWatch program using the contact information at the bottom of this page.
-
Safety Information
FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases
10/20/2010FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases
5/3/2010FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs
FDA press release (5/3/2010)Podcast for Healthcare Professionals: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases
5/6/2010
-
Contact FDA
1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem
Regular Mail: Use postage-paid FDA Form 3500
Mail to: MedWatch 5600 Fishers Lane
Rockville, MD 20857
-
-